AngioDynamics (ANGO)
AngioDynamics Long Term Debt: 6.345M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ANGO Long Term Debt Rankings
| Overall | 59th percentile | 1890 of 4657 |
| Sector | 42nd percentile | 304 of 525 in Healthcare |
| Industry | 41st percentile | 40 of 68 in Medical Instruments & Supplies |
ANGO Long Term Debt Range, Past 5 Years
| Minimum | 6.345M | Feb 2012 |
| Maximum | 17.43M | May 2007 |
| Average | 9.432M |
About Long Term Debt
Long-term debts are financial obligations and loans lasting longer than one year. A company must report long-term debt on its balance sheet with its date of maturity and interest rate.
Bonds and debt obligations with maturities greater than one year are examples of long-term debt. Other types of securities, including short-term notes and commercial papers usually are not long-term debt because their maturities typically are shorter than one year.
Learn More
You may also be interested in these ANGO related companies
ANGO News
AngioDynamics Completes Acquisition of Navilyst Medical http://stks.co/3vuI $ANGO
about 5 days ago by evcgroup
about 5 days ago by evcgroup
AngioDynamics Shareholders Approve Share Issuance for Navilyst Medical Acquisition
http://stks.co/3qGr $ANGO
about 12 days ago by evcgroup
about 12 days ago by evcgroup
AngioDynamics Shareholders Approve Share Issuance for Navilyst Medical Acquisition
May 15, 5:04PM GlobeNewswire
May 15, 5:04PM GlobeNewswire
RT @MedDevice ABC on Dr. Cunningham of @VeinClinics on the VenaCure 1470 for varicose veins bit.ly/VeinClinicsofAmericaBrentwood $ANGO
about 20 days ago by evcgroup
about 20 days ago by evcgroup
AngioDynamics' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Apr 04, 8:50PM Seeking Alpha
Apr 04, 8:50PM Seeking Alpha
Listen to $ANGO Q3 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3E55
about 53 days ago by earningscast
about 53 days ago by earningscast
NanoKnife® System Clinical Experience Featured at Society of Surgical Oncology Conference
Apr 02, 6:30AM Business Wire
Apr 02, 6:30AM Business Wire
Canaccord Genuity Maintains a 'Buy' on AngioDynamics (ANGO); Q3 Preview
Mar 30, 8:40AM Street Insider
Mar 30, 8:40AM Street Insider
AngioDynamics Establishes Strategic Relationship with Microsulis Medical Ltd.
Mar 26, 6:40AM Benzinga
Mar 26, 6:40AM Benzinga
AngioDynamics (ANGO) Invests, Enters Distribution Agreement with Microsulis Medical
Mar 26, 6:36AM Street Insider
Mar 26, 6:36AM Street Insider
AngioDynamics to Report Fiscal 2012 Third Quarter Financial Results and Hold Conference Call on April 4, 2012
Mar 21, 6:30AM GlobeNewswire
Mar 21, 6:30AM GlobeNewswire
AngioDynamics Receives FDA Clearance for NeverTouch Direct Procedure Kit to be Used With VenaCure EVLT System
http://stks.co/2OQd $ANGO
about 103 days ago by evcgroup
about 103 days ago by evcgroup
AngioDynamics Launches DuraFlow 2 Chronic Hemodialysis Catheter http://stks.co/2InF $ANGO
about 109 days ago by evcgroup
about 109 days ago by evcgroup
$ANGO 200 Day SMA Cross - Price crossed below 200 day SMA (14.4842). Confirmed by volume.
about 117 days ago by TradeIdeasQuant
about 117 days ago by TradeIdeasQuant
$ANGO Q3 adj-EPS from 9-11c to 7-9c, Q4 from 11-13c to 10-12c, FY12 from 41-45c to 38-42c
about 124 days ago by Street_Insider
about 124 days ago by Street_Insider
Listen to $ANGO Q2 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/1nIm
about 143 days ago by earningscast
about 143 days ago by earningscast
$ANGO Reports Q2 EPS $0.09 vs $0.12 Est; Revenues $58.10M vs $56.26M Est
about 143 days ago by Benzinga
about 143 days ago by Benzinga
AngioDynamics' new VenaCure 1470 in Houston http://stks.co/1PWW $ANGO
about 173 days ago by evcgroup
about 173 days ago by evcgroup
Listen to $ANGO at piper jaffray health care conference - live at 03:00 PM, ondemand after - http://stks.co/1KNG
about 179 days ago by earningscast
about 179 days ago by earningscast
AngioDynamics Expands Senior Leadership Team $ANGO http://stks.co/11Gy
about 201 days ago by evcgroup
about 201 days ago by evcgroup
RT @EVCGroup RT @MedDevice Here's where varicose vein treatment is today, a solid summary in Vascular Disease Management goo.gl/j3Vk1 $ANGO
about 205 days ago by evcgroup
about 205 days ago by evcgroup
$ANGO Reports Q1 EPS $0.08 vs $0.08 Est; Revenue $54.4M vs $53.86M Est; Announces Stock Repurchase Authorization of up to $20M
about 234 days ago by Benzinga
about 234 days ago by Benzinga
AngioDynamics $ANGO shares falling as FDA issues warning letter over NY plant inspection
about 271 days ago by Street_Insider
about 271 days ago by Street_Insider
After falling about 3% before the Nasdaq could halt, shares of $ANGO have bounced upon resumption, now down about 1.2% from today's close.
about 488 days ago by Street_Insider
about 488 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ANGO | 12.20 | -0.13 | -1.05% | 306.46M |
| ANGN | 5.85 | +0.20 | +3.54% | 22.93M |
| ANF | 36.23 | +0.94 | +2.66% | 3.069B |
| ANEN | 19.05 | +0.06 | +0.32% | 283.65M |
| ASPS | 57.98 | -1.04 | -1.76% | 1.352B |
| ASP | 11.61 | -0.05 | -0.46% | |
| ASNA | 18.90 | -0.02 | -0.11% | 2.896B |
| ASML | 46.00 | -0.22 | -0.48% | 19.03B |
| ASMI | 35.28 | -0.28 | -0.79% | 1.954B |
| ASM | 1.24 | -0.01 | -0.72% | 25.52M |
